Floatz Rating
B58/100
Confidence
Indicative
Sponsor
Tianjin Medical University Second Hospital
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
54High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06739395CT.gov Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion | — | Recruiting | — | — | — |
NCT02303028CT.gov Phase I Dose Escalation Study of Topotecan and Pazopanib in Children With Recurrent/Refractory Solid Tumours | — | Completed | — | — | — |
NCT02009449CT.gov A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors | — | Completed | — | — | — |
NCT01468922CT.gov Pazopanib and ARQ 197 for Advanced Solid Tumors | — | Completed | — | — | — |
NCT01485042CT.gov Dose Escalation Study of Pazopanib Plus TH-302 | — | Completed | — | — | — |
NCT01430572CT.gov Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients | — | Completed | — | — | — |
NCT01438554CT.gov Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma | — | Completed | — | — | — |
NCT01184326CT.gov Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer | — | Completed | — | — | — |
NCT01165385CT.gov Study With Pazopanib in Combination With Cisplatin (CDDP) in Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT01072890CT.gov Temsirolimus and Pazopanib in Patients With Advanced Solid Tumors | — | Completed | — | — | — |
Show 3 more trialsShow fewer
NCT00674024CT.gov Pazopanib to Treat Adults With Advanced Cancers and Varying Degrees of Liver Function | — | Completed | — | — | — |
NCT00561795CT.gov Feasibility Study of Pazopanib in Combination With Chemotherapy in Gynaecological Tumors | — | Completed | — | — | — |
NCT02354612CT.gov Open Label Continuation Study of TRC105 for Patients Who Have Completed a Prior TRC105 Trial | — | No Longer Available | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pazopanib (this asset) | Tianjin Medical University Second Hospital | P2 | B · 58 |
| Panitumumab | Astellas Pharma Inc | P2 | BBB |
| Granulocyte Colony-Stimulating Factor Lenograstim | Sanofi | P4 | BB |
| Dexmedetomidine | Medical College of Wisconsin | P4 | BB |
| Lidocaine | Medical College of Wisconsin | P4 | BB |
| Relatlimab | Bristol-Myers Squibb | P2 | BB |
| Vitamin D | Tanta University | P4 | BB |
| Glycopyrrolate | Medical College of Wisconsin | P4 | BB |
| Dinitrogen Monoxide | Medical College of Wisconsin | P4 | BB |
+42 more in the Neoplasm cohort
Other indications for Pazopanib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Renal Cell Carcinoma | — | P4 | BBB · 79 |
| Ovarian Neoplasm | — | P2 | BB · 71 |
| Non-Small Cell Lung Carcinoma | — | P2/3 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Pazopanib in Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pazopanib-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →